Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07792668

Pain Control During Hysterosalpingography: A Three-Arm Randomized Trial

Hysterosalpingography (HSG) is commonly performed during infertility evaluation and may cause pain during cervical manipulation, uterine distension, and contrast-medium injection. This prospective, randomized, three-arm controlled trial will compare three pain-control approaches during HSG: no analgesic premedication, rectal indomethacin administered before the procedure, and paracervical block with lidocaine. Eligible women scheduled for diagnostic HSG will be randomized in a 1:1:1 ratio. The primary outcome will be participant-reported pain during contrast-medium injection measured using an 11-point Numeric Rating Scale (NRS) ranging from 0 to 10. Secondary outcomes will include pain during other procedural stages, immediate and 30-minute post-procedural pain, preprocedural anxiety, anticipated pain, rescue analgesic requirement, participant satisfaction, and adverse events.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

About this study

Hysterosalpingography is an established diagnostic procedure used to assess tubal patency and uterine cavity morphology during infertility evaluation. Pain may occur at several procedural stages, including speculum insertion, cervical grasping, cannula placement, cervical traction, uterine distension, and contrast-medium injection.

This study is designed as a prospective, randomized, parallel-group, three-arm controlled superiority trial. Participants will be allocated in a 1:1:1 ratio to no premedication, rectal indomethacin, or paracervical block with lidocaine.

Pain intensity will be assessed using an 11-point Numeric Rating Scale ranging from 0, indicating no pain, to 10, indicating the worst imaginable pain. The primary outcome is pain during contrast-medium injection. Additional procedural pain scores, immediate post-procedural pain, pain at 30 minutes, preprocedural anxiety, anticipated pain, participant satisfaction, requirement for rescue analgesia, and adverse events will also be recorded.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female participants aged 18 to 45 years
  • Scheduled for diagnostic hysterosalpingography as part of infertility evaluation
  • Able to understand the study procedures and provide written informed consent
  • Able to report pain intensity using a 0-to-10 Numeric Rating Scale
  • Hysterosalpingography scheduled during the appropriate menstrual-cycle period according to routine institutional practice
  • Pregnancy excluded before hysterosalpingography according to routine institutional practice

Exclusion criteria

  • Pregnancy or suspected pregnancy
  • Active pelvic inflammatory disease or active genital tract infection
  • Known hypersensitivity or contraindication to indomethacin or other nonsteroidal anti-inflammatory drugs
  • Known hypersensitivity to lidocaine or other amide-type local anesthetics
  • Known hypersensitivity to the contrast medium used for hysterosalpingography
  • Active peptic ulcer disease or a history of clinically significant gastrointestinal bleeding
  • Significant renal or hepatic disease
  • Clinically significant bleeding disorder
  • Current anticoagulant therapy
  • Use of systemic analgesic, sedative, or antispasmodic medication within the predefined period before hysterosalpingography
  • Chronic pelvic pain requiring regular analgesic treatment
  • Severe dysmenorrhea requiring regular analgesic treatment
  • Cervical stenosis requiring anesthesia for hysterosalpingography Inability to provide reliable pain scores

Treatment and study plan

Indomethacin 25 MG/50 MG

Drug

A 50 mg indomethacin suppository will be administered rectally 30 minutes before hysterosalpingography.

Lidocaine %2 ampoule

Drug

A paracervical block will be performed using 2% lidocaine. Five milliliters of 2% lidocaine will be administered at the 4 o'clock position and 5 mL at the 8 o'clock position of the cervix, for a total volume of 10 mL and a total lidocaine dose of 200 mg. Injection depth will be approximately 1.5 to 3 cm. Hysterosalpingography will begin 5 minutes after completion of the paracervical block.

Primary outcomes

  1. Pain Intensity During Contrast-Medium Injection Measured Using the Numeric Rating Scale

    Time frame: During HSG, immediately after contrast-medium injection

    Participant-reported pain intensity will be measured using an 11-point Numeric Rating Scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater pain intensity.

Secondary outcomes

  1. Pain Intensity During Speculum Insertion

    Time frame: During HSG, immediately after speculum insertion

    Pain intensity measured using an 11-point NRS ranging from 0 to 10.

  2. Pain Intensity During Cervical Grasping

    Time frame: During HSG, immediately after tenaculum application or cervical grasping

    Pain intensity measured using an 11-point NRS ranging from 0 to 10.

  3. Pain Intensity During Cannula or Catheter Placement

    Time frame: During HSG, immediately after cannula or catheter placement

    Pain intensity measured using an 11-point NRS ranging from 0 to 10.

  4. Pain Intensity During Cervical Traction

    Time frame: During HSG, immediately after cervical traction

    Pain intensity measured using an 11-point NRS ranging from 0 to 10.

  5. Immediate Post-Procedural Pain Intensity

    Time frame: Within 5 minutes after completion of HSG

    Pain intensity measured using an 11-point NRS ranging from 0 to 10.

  6. Pain Intensity 30 Minutes After HSG

    Time frame: 30 minutes after completion of HSG

    Pain intensity measured using an 11-point NRS ranging from 0 to 10.

  7. Preprocedural State Anxiety

    Time frame: After informed consent and before randomization and administration of the study intervention

    Preprocedural state anxiety measured using the validated Turkish five-item short version of the State Anxiety Inventory (STAIS-5). Higher scores indicate greater state anxiety.

  8. Anticipated HSG Pain

    Time frame: Before randomization and administration of the study intervention.

    Expected pain during HSG measured using a single 0-to-10 Numeric Rating Scale.

  9. Participant Satisfaction With Pain Control

    Time frame: Immediately after HSG.

    Participant-reported satisfaction with pain control measured using a 0-to-10 scale, with higher scores indicating greater satisfaction.

  10. Requirement for Rescue Analgesia

    Time frame: From completion of HSG through 30 minutes after the procedure

    Number/percentage requiring additional analgesia.

  11. Participants With Adverse Events

    Time frame: From administration of the study intervention through 30 minutes after HSG

    Nausea, vomiting, dizziness, vasovagal symptoms, allergic symptoms, rectal discomfort, injection-site bleeding/hematoma, severe cramping, etc.

  12. Most Painful Procedural Step

    Time frame: Immediately after HSG

    Participant-reported most painful step during HSG.

Study contacts

Contact information is provided by the study sponsor or research team.

Sıla E DEMİRCAN, MD

CONTACT

[email protected]

+905301540874

Sponsors and collaborators

Lead sponsor

Balikesir University

Other

Registry information

Official study title

Comparison of No Premedication, Rectal Indomethacin Suppository, and Paracervical Block for Pain Reduction During Hysterosalpingography: A Prospective Randomized Three-Arm Controlled Trial

Acronym: HSG-PAIN

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Aug 28, 2026
Registry last updated
Aug 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.